Baptist Cancer Services offers patients participation in clinical trials. Following are the clinical trials currently available. For more information, contact our Baptist Cancer Services Navigator, Tonya Ball, at 601-974-6238.
Astra Zeneca-Phase 3 randomized study of Olaparib versus physician's' choice chemotherapy in metastatic breast cancer with germline BRACA 1/2 Mutations.
Merrimack - MM302 with Herceptin in advanced metastatic breast cancer
Novartis - Randomized study of Ribociclib in combination with Faslodex for advanced breast cancer
Puma Biotechnology - Neratinib plus Xeloda versus Tykerb plus Xeloda in patients with HER 2 positive metastatic breast cancer who have received two or more regimens for metastatic disease
Sanofi - Observational trial for metastatic colon cancer patients receiving Zaltrap in combination with FOLFIRI
Novartis - a phase 3 study trial of LGYX818 and MEK 162 and LX818 monotherapy compared with Vemurafenib in metastatic melanoma
Bristol Myers - Elotuzumab with Revlimid in relapsed or refractory multiple myeloma
Celgene– phase 3 randomized, double-blind study to compare efficacy and safety of Oral Azacitidine versus placebo plus best supportive care in subjects with RBC transfusion dependent anemia and thrombocytopenia due to IPSS lower risk MDS
What can we help you find?